Gritstone bio
GRTS
Market cap $6.14M

0.0520 USD

-0.0080

13.33%

At close Oct 17, 4:00 PM EDT

Pre-market

0.0489

-0.0031

5.96%

1 day

-13.33%

5 days

-19.38%

1 month

-90.72%

3 months

-92.57%

6 months

-93.02%

Year to date

-97.61%

1 year

-97.57%

5 years

-99.38%

About: Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.

Employees: 231

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

674% more call options, than puts

Call options by funds: $1.03M | Put options by funds: $133K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

9% less funds holding

Funds holding: 85 [Q1] → 77 (-8) [Q2]

18.75% less ownership

Funds ownership: 54.66% [Q1] → 35.91% (-18.75%) [Q2]

24% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 33

44% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 25

83% less capital invested

Capital invested by funds: $138M [Q1] → $24.1M (-$114M) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$0.50

862%

upside

Avg. target

$2.90

5,477%

upside

High target

$5

9,515%

upside

5 analyst ratings

3 positive

60%

2 neutral

40%

0 negative

0%

B. Riley Securities Mayank Mamtani 59% 1-year accuracy 16 / 27 met price target	1,823%upside $1	Neutral Downgraded	2 Oct 2024
HC Wainwright & Co. Sean Lee 22% 1-year accuracy 4 / 18 met price target	862%upside $0.50	Neutral Downgraded	1 Oct 2024
HC Wainwright & Co. Sean Lee 22% 1-year accuracy 4 / 18 met price target	7,592%upside $4	Buy Reiterated	15 Aug 2024
JMP Securities Roy Buchanan 33% 1-year accuracy 5 / 15 met price target	9,515%upside $5	Market Outperform Reiterated	5 Aug 2024
HC Wainwright & Co. Sean Lee 22% 1-year accuracy 4 / 18 met price target	7,592%upside $4	Buy Reiterated	5 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about GRTS published over the past 30 days

Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

EMERYVILLE, Calif.--(BUSINESS WIRE)--Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Gritstone intends to use the court-administered restructuring process to preserve value and support its ongoing strategic alternati.

Gritstone bio Takes Action to Preserve Value and Strengthen Capital Structure

Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'

On Monday, Gritstone Bio Inc. GRTS revealed interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline microsatellite-stable colorectal cancer (MSS-CRC).

Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Investors Have The Opportunity To Lead The Gritstone bio, Inc. Securities Fraud Lawsuit With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ:GRTS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

Investors Have The Opportunity To Lead The Gritstone bio, Inc. Securities Fraud Lawsuit With The Schall Law Firm

Zacks Investment Research

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates

Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.31 per share a year ago.

Gritstone bio Inc. (GRTS) Reports Q2 Loss, Misses Revenue Estimates

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer --

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Gritstone bio, Inc. (NASDAQ: GRTS) on behalf of long-term stockholders following a class action complaint that was filed against Gritstone on June 7, 2024 with a Class Period from March 9, 2023 to February 29, 2024. Our investigation concerns whether the board of directors of Gritstone have breached their fiduciary duties to the company.

GRITSTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Gritstone bio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Investors Are Invited To Take The Lead In The Gritstone Bio Inc Securities Fraud Case With The Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ: GRTS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

Investors Are Invited To Take The Lead In The Gritstone Bio Inc Securities Fraud Case With The Schall Law Firm

Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights – GRTS

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / If you suffered a loss on your Gritstone bio, Inc. (NASDAQ:GRTS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gritstone-lawsuit-submission-form?prid=94180&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Gritstone bio, Inc. Should Contact Levi & Korsinsky Before August 6, 2024 to Discuss Your Rights – GRTS

GRTS Investors Have The Opportunity To Lead Gritstone Bio Inc Securities Fraud Lawsuit With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gritstone bio, Inc. ("Gritstone" or "the Company") (NASDAQ: GRTS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 9, 2023 and February 29, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before August 6, 2024.

GRTS Investors Have The Opportunity To Lead Gritstone Bio Inc Securities Fraud Lawsuit With The Schall Law Firm

See News Rankings

Charts implemented using Lightweight Charts™